Center for Disaster Medicine Presents Operational Medicine Course for Law Enforcement 

CDM hosted a two-day course on Operational Medicine for law enforcement. Participants included 16 officers from the FBI, Homeland Security and local police departments from Mount Vernon, Mount Pleasant, Bedford, White Plains, City of Rye, Hastings-on-Hudson, Irvington and the Village of Mamaroneck. Officers were trained in didactic topics in basic tactical medicine, including sensory-impaired environments, direct threat care, indirect threat care and evacuation care. Read the full article on the CDM Operational Course and view the photo gallery. 

Film Screening and Discussion Helps Celebrate Black History Month

The NYMC community gathered to view the documentary, Aftershock, and engaged in in-depth discussion on the U.S. maternal health crisis on February 9, in recognition of Black History Month. The documentary examined the preventable deaths of two young Black women in New York City due to childbirth complications and followed their bereaved families who fought for justice and galvanized activists, birth workers and physicians to reckon with the U.S. maternal health crisis. The event was hosted by the Office of Diversity and Inclusion, Christian Medical and Dental Association, Obstetrics and Gynecology Student Interest Group, Student National Medical Association and the Universal Health Club. Read the full article on the movie screening and discussion.

Envisioning the Healthcare Landscape with ChatGPT

NYMC explores the opportunities and risks of artificial intelligence (AI) on the healthcare industry in the following article written entirely using ChatGPT. The healthcare industry is continuing to transform and adapt, driven in part by the advent of new technologies and innovations, including AI. An emerging technology that is poised to change the healthcare landscape, along with so many other industries, is ChatGPT. This AI-powered chatbot is designed to provide instant, accurate information and support to patients. While the technology offers exciting new opportunities, there are also risks associated with incorporating ChatGPT into the healthcare system that must be assessed, as well as ethical and legal considerations to be taken into account. Read the full article on IA and ChatGPT. 

Comorbidities and Hospital Length of Stay Key Mortality Predictors After Blunt Thoracic Trauma

Blunt thoracic trauma is responsible for 35 percent of trauma-related deaths in the United States and significantly contributes to morbidity and health care-related financial strain. A newly published study conducted by Guy Elgar, SOM Class of 2025, and Abbas Smiley, M.D., research assistant professor of surgery, found that comorbidities were a greater factor influencing mortality in emergently admitted patients with blunt chest wall trauma than advanced age, as had been reported in previous studies. Read the full article on blunt thoracic trauma.

Felipe C. Cabello, M.D., professor emeritus of pathology, microbiology and immunology, was an invited speaker at a virtual session on January 19, organized by ReAct, a global network dedicated to the problem of antimicrobial resistance, and its North American host, the Department of International Health at the Johns Hopkins Bloomberg School of Public Health. The session focused on the need to develop and implement policies for greater transparency on antimicrobial use in aquaculture. In his presentation, "Aquaculture and antimicrobial resistance and One Health," Dr. Cabello discussed the molecular epidemiology of antimicrobial resistance in aquaculture and its relevance for human and animal health and the environment. 

Test your knowledge on NYMC’s proud history of diversity and inclusion on Instagram during Black History Month. 

GRANTS CORNER

Fawaz Al-Mufti, M.D., associate professor of neurology, neurosurgery and of radiology, received a $172,517 grant from Cerus Endovascular, Inc. for "NECC: US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair."

Mitchell Cairo, M.D., professor of pediatrics, medicine, cell biology and anatomy and of pathology, microbiology and immunology, received a $1,004,658 grant from AbbVie Inc. for "A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms.” 

HeePeel Chang, M.D., clinical assistant professor of surgery, received a $5,000 grant from the Society for Vascular Surgery for "Efficacy and Safety of Intravascular Lithotripsy in Treatment of Chronic Limb-Threatening Ischemia."

George Coritsidis, M.D., professor of medicine, received a $7,000 grant from Natera, Inc., for "Renasight Testing in Underserved immigrant population with CKD of unknown etiology from Central and South America."

Victor Garcia, Ph.D., assistant professor of pharmacology, received a $56,000 grant for "Interdisciplinary Basic Medical School Sciences Program" and a $16,000 grant for "MAP to Success: A Medical Application Preparation Program at New York Medical College (NYMC)" from the Association of Medical Schools.

Jessica Hochberg, M.D., associate professor of pediatrics, received a $9,500 grant from CHOP for “ADVL1711 A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors.”

David Kronn, M.D., associate professor of pediatrics and of pathology, microbiology and immunology, received a $845,000 grant from Sanofi, Inc., for "Baby-COMET: Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa."

Delong Liu, M.D., Ph.D., professor of medicine, received a $41,516 grant from MorphoSys for “REAL-MIND: Prospective multicenter observational study of patients with relapsed or refractory diffuse large B-cell lymphoma starting second- or third-line therapy and not receiving autologous stem cell transplant.”

Srihari Naidu, M.D., professor of medicine, received a $92,211 grant from Cytokinetics, Inc. for “Protocol CY 6031 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate The Efficacy And Safety Of CK3773274 in Adults With Symptomatic Hypertrophic Cardiomyopathy nd Left Ventricular Outflow Tract Obstruction.”

Sheila Nolan, M.D., assistant professor of pediatrics, received a $22,096 grant from the NIH for "Comparative Effectiveness and Complications of Intravenous Ceftriaxone Compared with Oral Doxycycline in Lyme Meningitis in Children.”

Lance Parton, M.D., professor of pediatrics and associate professor of anesthesiology and of obstetrics and gynecology, received a $50,000 grant from the NIH for "Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (SILDI-SAFE).”

Tana Pradhan, D.O., clinical associate professor of obstetrics and gynecology, received a $103,545 grant from K-Beta Group, Inc/GOG Foundation for "A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alternations (Protocol ZN-c3-005)."

Karen Seiter, M.D., professor of medicine, received a $85,935 grant for "Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy” and a $65,620 grant for "A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome" (SELECT MDS-)" from Syros Pharma/CRO Precision for Medicine.

Gregory Veillette, M.D., assistant professor of surgery, received a $117,449 grant from Imvax, Inc. for "Evaluation of Immunological Responses Against Hepatocellular Carcinoma (Hcc) Tumors.”

John Welter, M.D., assistant professor of pediatrics, received a $288,790 grant from AbbVie for “A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation” and a $195,118 grant from Vertex Pharmaceuticals for “A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of Vx-121 Combination Therapy in Subjects with Cystic Fibrosis.”

Steven Wolf, M.D., clinical professor of pediatrics, received a $15,040 grant from Eisai for “Extended Access Program and Retrospective Chart Review For Locaserin in Dravet Syndrome and Other Refractory Epilepsies."